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A PPARγ fluorescence polarization (FP) assay was used to measure the release of fatty acid products from
triglyceride emulsions during digestion with pancreatic and yeast lipases in a real-time, homogenous assay. Using
the same FP assay we show the anti-obesity drug Orlistat is a PPARγ ligand with an IC50 of 2.84 ± 0.16 μM.
Analytical Mass Spectrometry confirms that Orlistat does not bind covalently to PPARγ. The PPARγ FP assay is
shown to be a simple method for measuring real-time lipase activity using a number of triglyceride substrates
including olive oil and grape seed oil emulsions. Incubation of Orlistat with the human intestinal epithelial cell line
Caco-2, at concentrations of 1 - 100 μM, leads to induction of genes regulated by PPARγ. At 100 μM Orlistat,
transcription of β-defensin 1 (hDB1) & Adipose Differentiation Related Protein (ADRP) increase by up to 2.6 fold and
6.8 fold, respectively. Although at 1 μM and 100 μM Orlistat did not significantly increase defensin protein synthesis,
at 10 μM Orlistat induced a 1.5 fold increase in hDB1 protein secretion in the human colonic adenocarcinoma cell
line HT-29. Thus Orlistat is similar to the anti-diabetic drug Rosiglitazone in its ability to induce defensin gene
expression. The antimicrobial peptide β-defensin 1 protects against pathogenic micro-organisms in the gut and
PPARγ suppresses inflammatory gene expression. These may be beneficial side effects of Orlistat consumption on
gut epithelial cells.
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The PPARγ agonist and anti-diabetic drug Rosiglitazone is
known to induce expression of the human β-defensin 1
(hBD1) gene in human intestinal epithelial Caco-2 cells
[1]. Defensins are cationic peptides expressed in phago-
cytic and epithelial cells that lyse micro-organisms by
forming pores in their membranes. Deficiency of defensin
expression is associated with colonisation of the gut with
Candida albicans [2] and also with Crohn’s disease [3].
Rosiglitazone has been used in the treatment of ulcerative
colitis [4] but it has been associated with adverse cardio-
vascular effects in the treatment of type 2 diabetes [5].
The lipase inhibiting drug Orlistat is marketed by Roche
under the trade name Xenical. It has a worldwide distribu-
tion and is used as an oral treatment for obesity [6].
Orlistat is also known as tetrahydrolipstatin and is a modi-
fied form of the streptomyces-derived lipase inhibitor
lipstatin [7]. Orlistat is very hydrophobic: (logP 7.6 - 8.1)* Correspondence: harry.martin@plantandfood.com
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reproduction in any medium, provided the orand binds covalently to the active site serine of pancre-
atic lipase [8]. Only trace amounts of Orlistat are
absorbed systemically and the drug remains almost entirely
in the gut lumen [9]. However, Orlistat penetrates cell
membranes sufficiently to have intracellular effects [10,11].
Liposarcoma cell growth is inhibited at a concentration of
20 μM via inhibition of the intracellular enzyme, fatty acid
synthase [12]. For this reason, Orlistat’s anti-cancer proper-
ties are being explored in a number of cancerous tissues
including colorectal [13], prostate [14] and leukemic cells
[15]. The extreme hydrophobicity of Orlistat led us to
speculate that it might also behave as a PPARγ agonist in
the gut epithelium where, due to its retention in the gut
lumen, the local Orlistat concentration is high.
PPARγ binding activity was assayed by fluorescence
polarization (FP) and mass spectrometry. Steady state
mRNA levels of some PPARγ regulated genes in human
Caco-2 epithelial cells were determined, including beta
defensin-1, (hBD1), adipose differentiation related pro-
tein (ADRP) and PPARγ itself. In addition, due to the
ability of PPARγ to bind a wide variety of fatty acids [16]Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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time assay for lipase activity.
Results
Real time lipase assay using PPARγ fluorescence
polarization method
Candida rugosa lipase and porcine pancreatic lipase were
incubated at concentrations ranging from 30 μg/mL to
3.3 μg/mL with various triglyceride emulsions in the pre-
sence of the FP reagents and polarization readings were
taken at 1–2 minute intervals for up to 30 minutes. The
PPARγ binding products released from the triglyceride
emulsions were detected by the FP assay. Figure 1A shows
the release of PPARγ binding products from digestion of
varying concentrations of grape seed oil emulsion with
Candida rugosa lipase. Figure 1B shows the release of
PPARγ binding products from triolein using different con-
centrations of porcine pancreatic lipase. Figure 1C shows
that release of PPARγ binding ligands during the digestion
of emulsions of three different substrates viz. grape seed
oil, triolein, and olive oil. To confirm the utility of the FP
assay as a lipase assay, the initial velocities (Vo) of the en-





















































Figure 1 Time course of triglyceride emulsion digestion measured by
triolein. Lipase concentration: 30 μg/mL (●), (□),▲ 3.3 μg/mL, no enzyme (○)
emulsion. Substrate concentration: 1.5 mg/mL (●), 0. 15 mg/mL (□), (▲) 0.015
at 0.15 mg/ml with 10 μg/ml Candida rugosa lipase: grape seed oil (●), olive o
change and fitted for initial rate using MonoMolecular Curve fit to determine
Figure 1A/1D.concentrations were estimated and shown to be linear
over a 9-fold dilution range (Figures 1D and 1E). These
experiments have been repeated at least three times and
the results shown are representative of the assay data
which are highly reproducible. Because the FP assay is car-
ried out in a 20 μl volume in a 384 well microplate, run-
ning replicates is simple and inexpensive.
Measurement of Orlistat binding to PPARγ by
Fluorescence Polarization
Although lipase activity is readily traced by the release of
fatty acids from the triglyceride substrate, the use of
PPARγ FP assay as a lipase assay has the limitation that
lipase inhibitors will tend to bind directly to the PPARγ
due to their hydrophobic nature. Figure 2 shows that
Orlistat is a PPARγ ligand with an IC50 of 2.84 μM, ±0.16.
By comparison, the PPARγ agonists Troglitazone and
Rosiglitazone are shown with IC50 values of 1.27 μM ±0.08
and 0.37 μM ±0.04 respectively.
Orlistat does not modify PPARγ covalently
Orlistat (Figure 2) forms a covalent adduct with pancreatic














a PPARγ FP assay. A: Porcine pancreatic lipase digestion of 1.5 mg/mL
. B: Candida rugosa lipase (10 μg/mL) digestion of grape seed oil
mg/mL, no substrate (○). C: Digestion of three different substrates each
il (□) and triolein (▲). D: Data from Figure 1A plotted as increasing mP
initial velocity. E: Initial velocities of lipase digestion reactions from









Figure 2 Dose response curves of Orlistat (○), Troglitazone (■) and Rosiglitazone (△) and 5-aminosalicylic acid (♦) in a PPARγ FP assay.
The structure of Orlistat is shown inset.
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Cys285 in the ligand binding pocket of PPARγ [17]. For
this reason we investigated the possibility of covalent
modification of PPARγ by Orlistat by mass spectrometry.
Orlistat was incubated in ammonium acetate buffer
pH 7.4 with PPARγ for 1 hour at room temperature and
then analysed by LCMS. The sulfhydryl-specific reagent
iodo-acetamido fluorescein (IAF) was included to confirm
that this procedure was able to detect covalent modifica-
tion of the PPARγ. The molecular weight of the PPARγ
was confirmed at 35,918 Da and is consistent with data
provided by the supplier. When IAF is added the molecu-
lar weight of PPARγ increased to 36,308 Da, an increase of
390 Da, consistent with the addition of IAF to a sulfhydryl
group on the PPARγ molecule. However, the molecular
weight of PPARγ remained at 35,319 Da when Orlistat
was added, suggesting that Orlistat does not form covalent
bonds with PPARγ (Figure 3). In addition, two covalent
PPARγ ligands, Dithio-bis (2-nitrobenzoic acid) and
GW9662, were also confirmed bind to PPARγ irreversibly
(data not shown).
Orlistat induces hBD1, ADRP & PPARγ mRNA expression
in Caco-2 cells
Treatment of Caco-2 human intestinal epithelial cells
with the PPARγ activator Rosiglitazone is known to in-
duce the induction and expression of the hBD1 gene
and Adipose Differentiation Related Protein (ADRP). To
determine whether Orlistat is also a PPARγ activator we
treated Caco-2 cells with 100 μM Orlistat or with 1 μM
Rosiglitazone for 24 hours before cells were harvested
for analysis of gene induction. Following the initial ob-
servation that 100 μM Orlistat induced hBD1 gene ex-
pression, the experiment was repeated using Orlistat at100, 10 and 1 μM. The results of both experiments are
shown in Figure 4. In the first experiment gene transcrip-
tion of hBD1, PPARγ, ADRP and were all significantly en-
hanced by treatment with 100 μM Orlistat by 3.0, 6.0 and
5.7 fold respectively and also by Rosiglitazone, the positive
control. In the second experiment, significant increases in
defensin gene transcription occurred at all three concen-
trations of Orlistat. Even at 1 μM Orlistat a 1.4 fold
increase in defensin transcription was observed. In the
second experiment, ADRP gene transcription was increased
by around seven fold using Orlistat at 100 μM and 10 μM
but no increase was observed at 1uM Orlistat. For reasons
unknown, the PPARγ gene induction seen in the first
experiment was not observed in the second experiment.Orlistat induces hBD1 protein expression in expression in
HT-29 cells
To establish whether the Orlistat and Rosiglitazone in-
duced β defensin1 mRNA expression was also associated
with an increase in β defensin1 protein synthesis, we first
performed a sandwich ELISA on the tissue culture super-
natants of Caco2 cells treated with Orlistat. We were
unable to detect β defensin1 protein in the Caco2 super-
natants although Caco2 are reported to synthesis β
defensin1 [18]. The related cell line HT-29 (a human co-
lonic adenocarcinoma) was then used as an alternative to
Caco2 (also human colorectal adenocarcinoma). Orlistat
& Rosiglitazone we tested at concentrations of 1, 10 and
100 μM for 24 h in culture. The supernatant was analysed
by sandwich ELISA for hBD1 protein and the results are
shown in Figure 5. Although the average defensin protein
was increased at all concentrations of drug treatment, sig-
nificant increases in defensin levels were only found at
Figure 3 The molecular weights of PPARγ and PPARγ conjugates were measured by ESI-MS. The software package DataAnalysis
(Bruker, Bremen, Germany) was used to average sample spectra and molecular weights calculated following charge deconvolution. The displayed
mass spectra are of the molecular ion containing 40 positive charges and clearly show that the molecular weight of PPARγ increased when IAF is
bound, indicating covalent binding. Whereas, there is no change in the molecular weight of PPARγ when Orlistat is bound, suggesting that the
binding of PPARγ to Orlistat is by non-covalent mechanisms.
































































Figure 4 Relative gene expression of hBD1, PPARγ and ADRP in Caco-2 cell following exposure to Orlistat, Rosiglitazone or DMSO
control for 24 h. Individual results were normalised to β-actin. Each bar represent mean ± SD (n=3). Significant differences between treatment
and control are shown as *(p<0.05).
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(~2 fold increase).
Discussion
The PPARγ FP assay provides a homogeneous and high-
throughput method (Figure 1) for continuous monitor-
ing of lipase reaction kinetics. The sensitivity of the
assay is determined by the affinity of the fatty acid pro-













































Figure 5 hBD1 protein expression in HT29 cell supernatants
and cell death following 24 h exposure to Orlistat,
Rosiglitazone and DMSO control. Each datapoint represents
mean ± SD (n=3). Significant differences between treatment and
control are shown as *(p<0.05). The dashed line indicates the upper
value of the error bar for the DMSO control sample. hBD1 protein in
DMSO control cell supernatant (Δ), hBD1 protein in Rosiglitazone
treated cell supernatant (○),hBD1 protein in Orlistat treated cell
supernatant (□). Tissue culture percent cell death at 24 h; DMSO
control cells (▲), cell death in Rosiglitazone treated cells (●),
cell death in Orlistat treated cells (■).PPARγ ligands is in the low micromolar range. Since
PPARγ is a non-selective binder of various fatty acids,
the assay is will not distinguish different lipase products.
The overlapping curves in Figure 1C may therefore re-
flect the formation of different products with different
affinities for PPARγ. Triolein yields oleic acid as a lipase
digestion product whereas around 70% of the fatty acid
content of grape seed oil is linoleic acid. The wide range
of fatty acids which are PPARγ ligands means that the
assay can be applied to the analyses of many lipases & sub-
strates. At high concentrations of substrate (Figure 1A,
1E), the rate of product formation is directly correlated
with lipase concentration whereas at low substrate con-
centrations (Figure 1B, 1C) a distinct lag period is evident
before product formation becomes detectable, giving the
reaction curve a sigmoidal appearance. The reasons for
the lag period are unclear at present and may reflect a
combination of causes; the use of substrate at concen-
trations lower than the lipase Km; partitioning of the
emulsion substrate and enzyme at low substrate concen-
trations; a low threshold of product formation may be re-
quired before the fluorescent ligand can be displaced from
the PPARγ receptor in the FP reaction. Nonetheless, as
Figure 1A shows, the FP assay is extremely simple and
sensitive as a method detecting and for quantifying lipase
in a sample. FP, as a ratiometric technique, is less sensitive
to sample colour and opacity than direct fluorescence
intensity methods. However, as the Orlistat data shows
(Figure 2) the PPARγ FP procedure is unlikely to permit
the analysis of lipase inhibitors since their lipophilicity will
tend to make them PPARγ ligands. It is well known that
cytosolic phospholipases initiate signal transduction path-
ways by releasing fatty acid signalling molecules from
phospholipid membranes and that many of the phospho-
lipase products are PPAR ligands. Thus, the in vitro gener-
ation of PPARγ ligands from lipase activity shown in
Figure 1 is analogous to the situation in cells whereby
Table 1 qPCR oligonucleotides and RT-qPCR efficiencies
for Caco-2 cells





ACTB, β-actin (NM_005345.4) F: GGAGTCCTACGCCTTCAACA
R: CCAGCACCTTCTTCTTGTCG
hBD1, Human β defensin 1 (X92744.1) F: TGTCTGAGATGGCCTCAG GT
R: GGGCAGGCAGAATAGAGACA




PPARγ variant 1 (NM_138712.3) F: GACAGGAAAGACAACAGAC
AAATC
R: GGGGTGATGTGTTTGAACTTG
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PPARδ ligands and the subsequent expression of PPARδ
dependent genes [19].
The possibility of covalent bond formation between
Orlistat & PPARγ was investigated because Orlistat binds
covalently to pancreatic and other lipases [8] and because
keto-fatty acids are known to form a covalent bond with
Cys285 in the ligand binding pocket of PPARγ [17]. The
mass spectrometry data shown in Figure 3 clearly demon-
strated that Orlistat, which contains 3 carbonyls [7], does
not bind covalently to PPARγ since no adduct was detect-
able by mass spectrometry.
The induction of beta defensin-1, and ADRP by
Orlistat (Figure 4) in Caco-2 cells along with the direct
binding of Orlistat to PPARγ (Figure 2), is strong evi-
dence that Orlistat is a PPARγ agonist since these genes
are known to be induced by the PPARγ agonist drugs
Troglitazone and Rosiglitazone [1,20]. In Figure 4,
Orlistat was used at a concentration as high as 100 μM
because this concentration in the gut lumen would be
achieved by the standard daily dose of 0.36 g Orlistat
[21] coupled with almost complete retention of the drug
in the in the gastrointestinal tract [9]. Although Orlistat
will induce cell death in human colonic adenocarcinoma
HT29 cells at a concentration of 100 μM over 48 hours
it does not induce cell death at 200 μM over a period of
24 hours [13] and it is far less toxic to normal cells than
to cancerous cells [14,15]. Furthermore, we see no evi-
dence of cell death in our Caco-2 culture, for example,
by detecting lower levels of control GAPDH RNA. Al-
though Rosiglitazone was slightly toxic to HT-29 cells at
100 μM (Figure 5) no evidence of toxicity was observed
at 10 μM at which a two-fold increase in β-defensin 1
protein was observed. Peyrin-Biroulet et al. (2010) has
shown that Rosiglitazone induced hBD1 mRNA. Our
data now confirms that hBD1 protein is also induced by
Rosiglitazone. Although the Orlistat induced defensin
protein is only increased by 1.5 fold at 10 μM, this may
result in a significant physiological effect in patients in
terms of pathogen resistance. A future study of the fae-
cal hBD1 protein content in Orlistat patients might con-
firm a PPARγ mediated physiological benefit of Orlistat.
Orlistat suppresses the onset of type 2 diabetes [22] due
the reduced calorific intake, and concomitant weight loss
of patients. As a consequence of Orlistat’s PPARγ agonist
activity, there may be local insulin sensitising effects in the
gut epithelium and additional physiological responses in-
cluding increased hBD1 and PPARγ transcription.
PPARγ activation is enhanced by the actions of cyto-
solic fatty acid binding proteins which deliver sparingly
soluble fatty acid ligands to the nucleus [23]. This raises
the question of whether Orlistat also binds to intracellu-
lar fatty acid binding proteins in gut epithelial cells and
what the consequences of that putative binding mightbe. Orlistat consumption is well known to cause steator-
rhea due to the arrival of undigested fat in the colon. Al-
though Orlistat is an irreversible inhibitor of pancreatic
lipase, it is a reversible inhibitor of certain bacterial li-
pases and not an inhibitor of a staphylococcal extracellular
lipase [24]. Some colonic digestion of fats is likely to occur
through bacterially-derived lipases in patients using
Orlistat. The fatty acids produced in these circum-
stances may induce PPARγ dependent gene transcrip-
tion in the epithelial cells of the intestine in the same way
that Orlistat affects Caco-2 cells. Thus, in addition to pro-
apoptotic side effects of Orlistat in colorectal carcinoma
cells [13], Orlistat may also induce anti-inflammatory
genes in gut tissue mediated by its PPARγ agonist activity.
Conclusions
The widely used lipase inhibitor drug Orlistat binds revers-
ibly to PPARγ with an IC50 of 2.8 μM. Orlistat acts on gut
epithelial Caco-2 cells as a PPARγ agonist and increases
synthesis of human defensin β1 and ADRP mRNA.
Methods
Chemicals and materials
Rosiglitazone, Troglitazone, 5-amino salicylic acid, GW9662
(a covalent binding PPARγ antagonist [25]), Orlistat, triolein
and iodo-acetamido-fluorescein were supplied by Sigma-
Aldrich. Grape seed oil and olive oil were commercial
brands from local supermarkets in Palmerston North,
New Zealand. LC-MS grade acetonitrile was from Thermo
Scientific, methanol (ChromAR) was from Mallinckrodt
Chemicals, and ethanol (95%) was from LabServ.
Fluorescence Polarization assay of PPARγ ligands
FP assays were performed on the Tecan Safire2 fluores-
cence microplate reader (Tecan, Austria) at 22°C, in a
volume of 20 μL in Nunc 384 well, black, shallow
microplates. The PPARγ (green) competitive binding
assay (PolarScreen™) kit was supplied by Invitrogen
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FP, excitation and emission wavelengths were set at
470 nm and 525 nm. Sigmoidal and exponential curve
fitting and IC50 and Vo estimates were performed with
Origin software (Origin-Lab, Northampton, MA, USA)
using the logistic and MonoMolecular equations respect-
ively. Data presented are representative of at least two
independent experiments.Lipase assays
Porcine pancreatic lipase (L3126) and Candida rugosa lip-
ase (L1754) was supplied by Sigma. Triolein, grape seed
oil & olive oil were used as triglyceride substrates for
lipase assays. Lipase substrate was prepared according to
the method of Nilsson-Ehle [26]. Briefly, substrate emul-
sions were prepared by mixing 240 mg triglyceride sub-
strate and 40 mg whey protein (WP1485) in 10 g glycerol.
200 μL of this stock solution was added to 800 μL 50 mM
Hepes buffer pH7.5 which was sonicated for six periods of
5 sec at 6 watts for each mL of assay mix. For FP assays,
the substrate emulsions were diluted in Invitrogen FP
PPARγ assay buffer to a final concentration of 0.15 mg/mL
triglyceride and digested with lipase for 30 minutes at 22°C
in volumes of 20 μL. During the digestion period, FP read-
ings were taken at 1 or 2 minute intervals.LC-QTOF-HRMS
The LC-MS system was composed of a Dionex Ultimate®
3000 Rapid Separation LC system and a micrOTOF QII
mass spectrometer (Bruker Daltonics, Bremen, Germany)
and was operating in positive mode with an electrospray
ionization source. The LC system contained a SRD-3400
solvent rack/degasser, HPR-3400RS binary pump, WPS-
3000RS thermostated autosampler, and a TCC-3000RS
thermostated column compartment. The analytical col-
umn was a Zorbax™ SB-C18 2.1 × 100 mm, 1.8 μm
(Agilent, Melbourne, Australia) maintained at 50°C and
operated in gradient mode. Solvents were A = 0.5%formic
acid, and B = 100%acetonitrile at a flow of 400 μL/min.
The gradient was: 70%A, 30%B, 0–0.5 min; linear gradient
to 45%A, 55%B, 0.5-25 min; linear gradient to 2%A, 98%B,
25–45 min; composition held at 2%A, 98%B, 45–50 min;
linear gradient to 70%A, 30%B, 50–50.2 min; to return to
the initial conditions before another sample injection at
54 min. The injection volume for samples and standards
was 2 μL. The micrOTOF QII source parameters were:
temperature 200°C; drying N2 flow 8 L/min; nebulizer N2
4.0 bar, endplate offset -500 V, capillary voltage −4000 V;
mass range 100–1500 Da, acquired at 2 scans/s. Post-
acquisition internal mass calibration used sodium formate
clusters with the sodium formate delivered by a syringe
pump at the start of each chromatographic analysis.Tissue culture
Caco-2 cells and HT-29 cells were cultured in DMEM
supplemented with 5%Foetal bovine serum, glutamine &
antibiotics at 37°C, 5%CO2. Test compounds in DMSO
were tested in triplicate by addition of 1 μl of test com-
pound to 1 ml cell culture for 24 h.
Real-Time RT-PCR
Total RNA was extracted by the use of High Pure RNA
Isolation Kit and reverse transcription performed using
Transcriptor First Strand cDNA Synthesis kit with oligo-
dT primed reactions, both according to manufacturer’s
instructions (Roche Diagnostics, New Zealand). Primers
and primer-dual hybridisation probe combinations (Roche
Diagnostics, Germany-Table 1) were designed online
using the Universal probe library system assay design
centre (Roche Applied Science). The RT-qPCR assay was
performed using the Lightcycler® 480 system (Roche
Diagnostics, Germany) with three reactions (technical
replicates) for each sample. Real-time PCR parameters are
as follows: 10 minutes (0:10:00) pre-incubation at 95°C,
40 cycles of amplification from 95°C (0:00:10), to 58°C
(0:00:20), to 72°C (0:00:01), followed by cooling at 40°C
(0:00:10). Results were relative to the expression of
glyceraldehyde-3-phosphate dehydrogenase and β-actin,
however the latter produced most consistent expression
between samples and was used as the reference gene to
calculate final relative expression.
Statistical analysis
Quantitative RT-PCR results were analysed using inbuilt
relative quantification software (Light –Cycler 480 soft-
ware version 1.0), using the standard curve for both tar-
get and reference (ACTB) gene and the software then
determined the target to reference ratio.
β-defensin ELISA
24 h tissue culture supernatants were analysed in triplicate
for human-β defensin 1 using a commercial sandwich
ELISA kit supplied by Genway, San Diego.
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